Cigna · Forteo · US health-plan appeal rights

Forteo denied due to quantity / dose limits by Cigna?

Q: How long do I have to appeal a Cigna Forteo denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Cigna typically requires

Cigna's specific coverage criteria for forteo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Cigna / Express Scripts the applicable coverage policy — Anabolic Osteoporosis Agents (Forteo / Tymlos)

The Cigna angle on Forteo

## Why Cigna Denied Forteo for Quantity Limits

Quantity-limit (QL) denials for teriparatide (Forteo) typically occur in one of two situations: the prescription was written for a supply or administration frequency that exceeds Cigna's allowed quantity per fill or per coverage period, or the plan imposes a maximum cumulative duration limit and your prior usage is approaching or has reached it. Teriparatide has a labeled maximum treatment duration, and Cigna's QL may track it — but the plan's limit and the label's limit may be calculated differently, leading to premature denials.

## Federal Appeal Framework

Internal appeal: File within the deadline in your denial letter. For non-urgent supply requests, Cigna has 30 days to decide. If you are running out of medication and delay could affect your health, request expedited review (72-hour decision).
External review (ACA §2719 / ERISA §503): After an internal denial, you may request independent external review within approximately 4 months. An independent reviewer evaluates whether the quantity limit as applied to your clinical situation is medically appropriate. Expedited review is available when health is at serious risk.

## Documentation to Gather

1. Actual usage documentation: A complete, dated pharmacy and claims history confirming exactly how much teriparatide has been dispensed to you and when, so the cumulative duration can be calculated accurately. 2. Prescribing label review: Confirm with your prescriber the maximum treatment duration as stated in the current FDA-approved prescribing label. If Cigna's limit is shorter than the label allows, that discrepancy is your central appeal argument. 3. Physician medical-necessity statement: A letter from the treating physician documenting your current clinical status, the therapeutic benefit observed, and why continued therapy within the label-permitted duration is medically necessary. 4. Diagnosis and severity updates: Current DXA results or fracture-risk assessment showing ongoing clinical need.

## Criteria-Mapping Structure

Obtain Cigna's quantity-limit policy for teriparatide from the formulary or coverage documents. Compare it against the FDA prescribing label's stated duration guidance. Document the exact number of days of therapy dispensed to date using pharmacy records. Present the calculation clearly: total dispensed, remaining label-allowed duration, and the clinical rationale for the requested quantity. A factual, number-supported calculation is the most effective format for a quantity-limit appeal.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Cigna appeals

Other denial reasons for Cigna Forteo

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.